In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption

We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody, mAb)-trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2(low) human pancreatic carcinoma xenografts. Here, we compared the 2mAbs therapy, the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Larbouret, Christel, Gaborit, Nadège, Chardès, Thierry, Coelho, Mickaël, Campigna, Emmanuelle, Bascoul-Mollevi, Caroline, Mach, Jean-Pierre, Azria, David, Robert, Bruno, Pèlegrin, André
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press Inc. 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306257/
https://ncbi.nlm.nih.gov/pubmed/22431920
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky